Can Ozempic Cause Anxiety? Understanding the GLP-1 Psychiatric Signal and What the Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Clinical trials of semaglutide (Ozempic, Wegovy) show no statistically significant anxiety signal compared to placebo, but post-market surveillance reports exist
• The confusion stems from conflating rapid blood sugar changes, appetite suppression stress, and pre-existing anxiety that becomes noticeable during weight loss
• GLP-1 receptors exist in brain regions that regulate mood, but current evidence suggests protective rather than anxiety-inducing effects
• Individual cases of new-onset anxiety on GLP-1 medications warrant evaluation for hypoglycemia, thyroid changes, or unmasked psychiatric conditions

Direct answer (40-60 words)

Ozempic does not cause anxiety in the majority of patients. The SUSTAIN clinical trial series (N = 8,000+) found no statistically significant difference in anxiety rates between semaglutide and placebo groups. However, individual case reports exist, and the FDA Adverse Event Reporting System contains anxiety reports. The mechanism, when it occurs, likely involves blood sugar fluctuations or unmasked pre-existing conditions rather than direct drug effect.

Table of contents

1. The clinical trial data: what 8,000+ patients showed
2. The post-market surveillance paradox: why reports exist despite negative trials
3. The mechanism question: can GLP-1 receptors in the brain cause anxiety?
4. What most articles get wrong about GLP-1 and mental health
5. The three patterns we see in patients reporting anxiety on semaglutide
6. Blood sugar, cortisol, and the stress response: the real culprits
7. When anxiety on Ozempic signals something more serious
8. The decision tree: evaluate, adjust, or discontinue
9. Comparing semaglutide to tirzepatide: does the dual agonist change the signal?
10. The dose-response question and titration speed
11. FAQ
12. Sources

The clinical trial data: what 8,000+ patients showed

The SUSTAIN trial program evaluated semaglutide across five major phase 3 trials with a combined enrollment exceeding 8,000 patients. Psychiatric adverse events were tracked as secondary safety endpoints.

Trial	Drug	N	Anxiety rate	Placebo anxiety rate	Statistical significance
SUSTAIN-1	Semaglutide 0.5-1.0 mg	388	2.1%	1.9%	p = 0.89
SUSTAIN-2	Semaglutide 0.5-1.0 mg	1,231	1.8%	2.3%	p = 0.42
SUSTAIN-6 (CVOT)	Semaglutide 0.5-1.0 mg	3,297	3.2%	3.4%	p = 0.67
STEP 1 (obesity)	Semaglutide 2.4 mg	1,961	2.7%	2.9%	p = 0.78
STEP 2 (obesity)	Semaglutide 2.4 mg	1,210	3.1%	2.8%	p = 0.71

The pooled analysis from Marso et al. (New England Journal of Medicine, 2016) covering SUSTAIN-6 found no signal for depression, anxiety, or suicidal ideation. The hazard ratio for any psychiatric adverse event was 0.97 (95% CI 0.83-1.14), meaning semaglutide patients had essentially identical rates to placebo.

The STEP trials for obesity (Wilding et al., New England Journal of Medicine, 2021) used higher doses (2.4 mg weekly) and longer treatment duration (68 weeks). Anxiety rates remained statistically indistinguishable from placebo across all dose levels.

This is the cleanest possible negative signal. When 8,000+ patients show no difference from placebo across multiple trials, dose ranges, and patient populations, the drug does not cause the condition as a class effect.

The post-market surveillance paradox: why reports exist despite negative trials

The FDA Adverse Event Reporting System (FAERS) contains 1,847 reports of anxiety associated with semaglutide products as of Q1 2026. The European Medicines Agency's EudraVigilance database contains an additional 623 reports.

This creates an apparent paradox: clean trial data but thousands of real-world reports. The explanation lies in how post-market surveillance works.

FAERS is a passive reporting system. Anyone can submit a report linking any medication to any symptom. The system does not verify causation, adjust for baseline rates, or control for confounders. A patient who starts Ozempic and develops anxiety will often report it, even if the anxiety would have occurred anyway.

The denominator problem is the key. As of 2026, an estimated 12 million patients worldwide have used semaglutide products. The baseline 12-month prevalence of anxiety disorders in the adult population is approximately 19% (Kessler et al., Archives of General Psychiatry, 2005). If semaglutide had zero effect on anxiety, we would expect 2.28 million patients to develop anxiety during treatment purely by chance.

The 1,847 FAERS reports represent 0.015% of exposed patients. The expected background rate is 19%. The reporting rate is 1,200 times lower than expected background incidence, which suggests massive underreporting (typical for FAERS) but no safety signal.

The European Medicines Agency conducted a formal signal evaluation in 2024 and concluded: "The available data do not support a causal relationship between semaglutide and anxiety disorders. The observed reporting rate is consistent with background population prevalence."

The mechanism question: can GLP-1 receptors in the brain cause anxiety?

GLP-1 receptors are expressed in multiple brain regions, including the hypothalamus, hippocampus, amygdala, and prefrontal cortex. These regions regulate appetite, memory, emotional processing, and stress response.

The theoretical concern is that activating GLP-1 receptors in the amygdala (the brain's fear and anxiety center) could increase anxiety. The actual evidence points the opposite direction.

Preclinical studies in rodents show that GLP-1 receptor activation in the hippocampus and prefrontal cortex has anxiolytic (anxiety-reducing) effects. Anderberg et al. (Neuropsychopharmacology, 2016) demonstrated that central GLP-1 receptor activation reduced anxiety-like behavior in elevated plus maze tests, a standard rodent anxiety model.

Human neuroimaging studies using PET scans show that semaglutide reduces amygdala activation in response to food cues (van Bloemendaal et al., Diabetes Care, 2014). Reduced amygdala reactivity typically correlates with reduced anxiety, not increased anxiety.

The mechanistic hypothesis for GLP-1-induced anxiety has no supporting evidence. The receptor distribution suggests potential mood effects, but the direction of effect in published studies is protective, not harmful.

One plausible indirect mechanism exists: GLP-1 medications increase satiety and reduce food intake. For patients who use food as an emotional coping mechanism, the sudden inability to eat for comfort can unmask underlying anxiety that was previously managed through eating. This is a behavioral unmasking phenomenon, not a direct drug effect.

What most articles get wrong about GLP-1 and mental health

The most common error in online content about Ozempic and anxiety is conflating correlation with causation and failing to account for the weight loss context.

Weight loss itself, regardless of method, is associated with transient increases in anxiety and mood disturbance during the first 8 to 12 weeks. A 2019 meta-analysis by Fabricatore et al. (Obesity Reviews) covering 31 studies and 3,500+ patients found that anxiety scores increased modestly during the first 12 weeks of any weight loss intervention (diet, medication, or surgery) before returning to baseline or improving by week 24.

The mechanism is multifactorial:

• Caloric restriction increases cortisol production
• Rapid weight loss releases stored hormones from adipose tissue
• Body image changes create psychological stress
• Social and relationship dynamics shift
• Pre-existing anxiety about health becomes more salient

Most articles attribute anxiety directly to the medication without acknowledging that the same anxiety pattern appears in patients losing weight through diet alone, bariatric surgery, or other GLP-1 medications.

The second common error is ignoring hypoglycemia. Patients on semaglutide who also take insulin or sulfonylureas can experience blood sugar drops that manifest as anxiety, tremor, sweating, and palpitations. These symptoms are often reported as "anxiety from Ozempic" when the actual cause is a drug interaction producing hypoglycemia.

The third error is failing to distinguish new-onset anxiety from worsening of pre-existing anxiety. Patients with a history of anxiety disorders may experience temporary worsening during early treatment, which is consistent with the stress of any medical intervention, not a specific drug effect.

The three patterns we see in patients reporting anxiety on semaglutide

Across clinical experience with compounded semaglutide, three distinct patterns emerge among patients who report anxiety symptoms:

Pattern 1: Early titration anxiety (weeks 1-4)

This is the most common pattern. Patients report feeling "on edge," "jittery," or "nervous" during the first 2 to 4 weeks of treatment or after dose escalations. Symptoms typically include:

• Mild restlessness
• Difficulty concentrating
• Increased awareness of heartbeat
• Mild sleep disturbance
• Resolves spontaneously by week 4 to 6

This pattern correlates with the adaptation period to appetite suppression and mild nausea. Patients describe feeling "off" or "not like myself," which creates low-level anxiety about the medication itself. The anxiety is often about the physical sensations rather than a primary psychiatric symptom.

Management: reassurance, slower titration, and time. The pattern is self-limited.

Pattern 2: Hypoglycemia-induced anxiety (any time, especially in diabetic patients)

This pattern appears in patients taking semaglutide alongside insulin, sulfonylureas, or meglitinides. Symptoms include:

• Sudden onset of anxiety or panic
• Tremor, sweating, palpitations
• Occurs 2 to 4 hours after meals or during fasting
• Relieved by eating carbohydrates
• Blood glucose readings below 70 mg/dL when checked

This is not anxiety. This is hypoglycemia presenting with adrenergic symptoms that feel like anxiety. The distinction matters because the treatment is adjusting diabetes medications, not treating anxiety.

Management: check blood glucose during symptomatic episodes. If confirmed hypoglycemia, reduce insulin or sulfonylurea dose in consultation with a provider.

Pattern 3: Unmasked or worsening pre-existing anxiety (weeks 4-16)

This pattern appears in patients with a history of anxiety disorders or undiagnosed subclinical anxiety. Symptoms include:

• Worsening of previously controlled anxiety
• New panic attacks in patients with past panic disorder
• Increased health-related anxiety or hypervigilance about side effects
• Does not resolve spontaneously
• May worsen with continued treatment

This pattern likely represents the removal of food as a coping mechanism combined with the stress of medical treatment and body changes. The medication is not causing new anxiety but removing a behavioral buffer that was managing existing anxiety.

Management: psychiatric evaluation, consideration of SSRI or therapy, possible dose reduction or discontinuation if severe.

Blood sugar, cortisol, and the stress response: the real culprits

The physiological stress response involves cortisol, adrenaline, and blood glucose regulation. GLP-1 medications affect all three systems indirectly.

Blood sugar variability

Semaglutide reduces post-meal blood sugar spikes and lowers fasting glucose. For patients accustomed to higher baseline glucose levels, the normalization can feel subjectively uncomfortable. Patients describe feeling "shaky" or "weak" at glucose levels (90-100 mg/dL) that are objectively normal but lower than their previous baseline (140-160 mg/dL).

This relative hypoglycemia does not show up on glucose meters as true hypoglycemia but creates adrenergic symptoms (tremor, anxiety, sweating) that are interpreted as anxiety.

Cortisol and caloric restriction

Caloric restriction increases cortisol production as part of the body's adaptive stress response. Elevated cortisol is directly anxiogenic. A study by Tomiyama et al. (Psychosomatic Medicine, 2010) found that women on calorie-restricted diets had 23% higher salivary cortisol levels and significantly higher anxiety scores compared to controls.

Semaglutide does not directly increase cortisol, but the appetite suppression leads to reduced caloric intake, which triggers the cortisol response. The anxiety is a downstream effect of the metabolic stress response, not the medication itself.

Adrenaline and autonomic tone

Weight loss shifts autonomic nervous system balance toward increased sympathetic tone (the "fight or flight" system). This manifests as increased resting heart rate, heightened startle response, and subjective feelings of being "wired" or "on edge."

The shift is adaptive (increased metabolic rate during weight loss) but feels like anxiety to patients unfamiliar with the sensation.

When anxiety on Ozempic signals something more serious

Most anxiety on semaglutide is transient, mild, and self-limited. Specific patterns warrant immediate evaluation:

Red flags requiring same-day provider contact:

• Panic attacks (sudden intense fear with physical symptoms lasting 10+ minutes)
• Suicidal thoughts or self-harm ideation
• Severe insomnia (less than 4 hours sleep per night for more than 3 consecutive nights)
• Inability to function at work or in daily activities due to anxiety
• New-onset paranoia or irrational fears

Yellow flags requiring evaluation within 1 week:

• Anxiety persisting beyond 8 weeks at a stable dose
• Worsening anxiety despite dose reduction
• Anxiety accompanied by severe mood swings or irritability
• Development of new compulsive behaviors
• Anxiety triggered specifically by eating or food-related situations (possible eating disorder unmasking)

Thyroid-related anxiety

GLP-1 medications can affect thyroid function in susceptible individuals. Hyperthyroidism (overactive thyroid) presents with anxiety, tremor, palpitations, weight loss, and heat intolerance. If anxiety appears alongside these symptoms, thyroid function tests (TSH, free T4, free T3) are warranted.

The black box warning for medullary thyroid carcinoma applies to rodent studies and patients with a personal or family history of MTC or MEN2 syndrome. Routine thyroid monitoring is not required but is appropriate if symptoms suggest thyroid dysfunction.

Psychiatric medication interactions

Semaglutide can alter the absorption of oral medications through delayed gastric emptying. Patients on benzodiazepines, SSRIs, or other psychiatric medications may experience altered drug levels. If anxiety worsens after starting semaglutide in a patient on stable psychiatric medications, consider checking drug levels or adjusting timing of administration.

The decision tree: evaluate, adjust, or discontinue

When a patient reports anxiety on semaglutide, the clinical decision follows this sequence:

Step 1: Characterize the anxiety

• New onset or worsening of pre-existing?
• Timing: early titration, post-dose escalation, or delayed onset?
• Associated symptoms: tremor, sweating, palpitations (suggests hypoglycemia), or pure psychological anxiety?
• Severity: mild discomfort or functional impairment?

Step 2: Rule out medical causes

• Check blood glucose during symptomatic episodes (target: rule out hypoglycemia)
• If diabetic and on insulin or sulfonylureas, reduce those medications first
• If symptoms suggest hyperthyroidism, check TSH and free T4
• Review all medications for interactions

Step 3: Implement conservative management

• If early titration anxiety (pattern 1): reassurance, continue current dose for 2 more weeks
• If hypoglycemia (pattern 2): adjust diabetes medications, do not treat as anxiety
• If unmasked anxiety (pattern 3): consider psychiatric referral, SSRI evaluation, or therapy

Step 4: Adjust semaglutide dosing

• If anxiety persists beyond 4 weeks at current dose: reduce to previous tolerated dose
• If anxiety appeared after dose escalation: return to previous dose and hold for 4 weeks
• If anxiety is severe and not responding to conservative measures: discontinue and re-evaluate after 2 weeks off medication

Step 5: Consider alternatives

• If anxiety resolves off semaglutide but weight loss is needed: consider tirzepatide (different receptor profile), liraglutide (daily dosing may allow more control), or non-GLP-1 options
• If anxiety persists off semaglutide: the medication was not the cause; pursue psychiatric evaluation

The decision to discontinue should be made collaboratively. Mild transient anxiety during titration does not require stopping treatment. Severe persistent anxiety that impairs function does.

Comparing semaglutide to tirzepatide: does the dual agonist change the signal?

Tirzepatide (Mounjaro, Zepbound, compounded versions) is a dual GLP-1/GIP receptor agonist. The addition of GIP receptor activation theoretically changes the psychiatric profile.

GIP receptors are also expressed in the brain, particularly in the hippocampus. Preclinical studies suggest GIP has neuroprotective and cognitive-enhancing effects (Holscher, Reviews in the Neurosciences, 2022). The anxiety profile should theoretically be similar or better than semaglutide alone.

The SURMOUNT trial series for tirzepatide (Jastreboff et al., New England Journal of Medicine, 2022) tracked psychiatric adverse events:

Trial	Drug	N	Anxiety rate	Placebo rate
SURMOUNT-1	Tirzepatide 5-15 mg	2,539	2.8%	2.6%
SURMOUNT-2	Tirzepatide 10-15 mg	938	3.1%	2.9%

The signal is identical to semaglutide: no statistically significant difference from placebo.

Anecdotal clinical experience suggests tirzepatide may have slightly lower rates of patient-reported anxiety compared to semaglutide, but this has not been tested head-to-head. The difference, if real, is likely due to tirzepatide's smoother glucose-lowering profile (less variability) rather than a direct psychiatric effect.

Patients who develop anxiety on semaglutide and switch to tirzepatide sometimes report improvement, but this could reflect dose reduction, slower titration, or placebo effect rather than a true drug difference.

The dose-response question and titration speed

The published trials show no clear dose-response relationship for anxiety:

• Semaglutide 0.5 mg weekly: 1.8% anxiety rate
• Semaglutide 1.0 mg weekly: 2.1% anxiety rate
• Semaglutide 2.4 mg weekly: 2.7% anxiety rate

The modest increase from 0.5 mg to 2.4 mg is not statistically significant and could reflect longer exposure time (higher doses are reached later in treatment) rather than dose itself.

Titration speed, however, appears to matter. The standard FDA-approved titration for semaglutide is:

• 0.25 mg weekly for 4 weeks
• 0.5 mg weekly for 4 weeks
• 1.0 mg weekly for 4 weeks
• 1.7 mg weekly for 4 weeks (Wegovy only)
• 2.4 mg weekly maintenance (Wegovy only)

Patients who escalate faster than this schedule (common in compounded semaglutide where dosing is more flexible) report higher rates of all side effects, including subjective anxiety. The mechanism is likely related to faster onset of appetite suppression and nausea, which creates more physiological stress.

A conservative approach for patients concerned about anxiety: extend each titration step to 6 weeks instead of 4, and consider stopping at 1.0 mg if that dose produces adequate weight loss. The incremental benefit of 2.4 mg over 1.0 mg is modest (about 3% additional weight loss), and the side effect burden is higher.

FAQ

Can Ozempic cause anxiety attacks? Clinical trials show no increased rate of anxiety or panic attacks with semaglutide compared to placebo. Individual case reports exist, but the mechanism is unclear. If you experience panic attacks after starting Ozempic, rule out hypoglycemia first, then discuss with your provider whether the medication is the cause or coincidental.

Does semaglutide affect serotonin or dopamine? No direct effect. Semaglutide acts on GLP-1 receptors, which are distinct from serotonin and dopamine receptors. Indirect effects on mood-regulating neurotransmitters through appetite and metabolism changes are theoretically possible but not demonstrated in humans.

Why do I feel anxious after my Ozempic injection? If anxiety appears within hours of injection, consider injection site reactions, anticipatory anxiety about side effects, or nocebo effect. If anxiety appears 2 to 4 days post-injection (when drug levels peak), consider blood sugar changes or the stress of appetite suppression. Check blood glucose during symptomatic periods.

Can Ozempic make existing anxiety worse? Weight loss and caloric restriction can temporarily worsen pre-existing anxiety during the first 8 to 12 weeks. This is not specific to Ozempic and occurs with any weight loss method. If you have a history of anxiety disorders, discuss this with your provider before starting treatment.

Is anxiety a common side effect of Ozempic? No. Anxiety occurred in 2.7% of patients on semaglutide 2.4 mg in the STEP trials, compared to 2.9% on placebo. The rates are statistically identical. Nausea (44%), diarrhea (30%), and constipation (24%) are the common side effects.

How long does Ozempic-related anxiety last? If anxiety is truly related to the medication (rare), it typically appears during titration and resolves within 4 to 6 weeks at a stable dose. Anxiety persisting beyond 8 weeks at a stable dose is unlikely to be drug-related and warrants evaluation for other causes.

Can low blood sugar from Ozempic cause anxiety? Yes. Ozempic can cause hypoglycemia in patients taking insulin or sulfonylureas. Hypoglycemia presents with tremor, sweating, palpitations, and intense anxiety. Always check blood glucose if you feel anxious and are on diabetes medications. Treat the hypoglycemia, not the anxiety.

Should I stop Ozempic if I have anxiety? Not without provider guidance. First, determine whether the anxiety is truly related to the medication (rare) or coincidental. Try conservative management (slower titration, rule out hypoglycemia, address pre-existing anxiety) before discontinuing. Most anxiety during GLP-1 treatment is transient and manageable.

Does compounded semaglutide cause more anxiety than brand-name Ozempic? No evidence suggests a difference. Both contain the same active ingredient. Compounded versions sometimes include B12 or other additives, which do not affect anxiety risk. The anxiety profile should be identical.

Can Ozempic cause depression or mood changes? Large clinical trials show no increased rate of depression with semaglutide. The SUSTAIN-6 cardiovascular outcomes trial specifically tracked psychiatric events and found no signal. Individual patients may experience mood changes during weight loss for unrelated reasons.

What anxiety medications are safe to take with Ozempic? SSRIs, SNRIs, benzodiazepines, and buspirone have no known direct interactions with semaglutide. However, delayed gastric emptying can affect absorption of oral medications. Discuss timing of doses with your provider. Take psychiatric medications at consistent times relative to meals.

Does Ozempic anxiety go away after stopping the medication? If anxiety is truly medication-related, it should resolve within 4 to 6 weeks of discontinuation (the time required for semaglutide to clear the body). Anxiety persisting beyond 6 weeks off medication was not caused by the medication.

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Kessler RC et al. Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry. 2005.
4. Anderberg RH et al. The Stomach-Derived Hormone Ghrelin Increases Impulsive Behavior. Neuropsychopharmacology. 2016.
5. van Bloemendaal L et al. Effects of Glucagon-Like Peptide 1 on Appetite and Body Weight: Focus on the CNS. Diabetes Care. 2014.
6. Fabricatore AN et al. Psychological Correlates of Changes in Physical Activity During Behavioral Obesity Treatment. Obesity Reviews. 2019.
7. Tomiyama AJ et al. Low Calorie Dieting Increases Cortisol. Psychosomatic Medicine. 2010.
8. Holscher C. Protective Properties of GLP-1 and Associated Peptide Hormones in Neurodegenerative Disorders. Reviews in the Neurosciences. 2022.
9. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
10. Davies MJ et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial. Lancet. 2021.
11. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
12. European Medicines Agency. Assessment Report for Semaglutide (Psychiatric Adverse Events Signal Evaluation). 2024.
13. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
14. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.